切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2021, Vol. 15 ›› Issue (06) : 429 -431. doi: 10.3877/cma.j.issn.1674-0793.2021.06.006

论著

散发性甲状腺髓样癌原发灶的切除范围及预后分析
赵敬柱1, 郑向前1, 高明2,(), 池嘉栋1, 运新伟1, 李大鹏1, 阮先辉1   
  1. 1. 300060 天津医科大学肿瘤医院甲状腺颈部肿瘤科,国家肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心
    2. 300121 天津市人民医院乳腺甲状腺科
  • 收稿日期:2021-03-09 出版日期:2021-12-01
  • 通信作者: 高明
  • 基金资助:
    天津市重点研发计划科技支撑重点项目(17YFZCSY00690)

Surgical selection and prognostic analysis of sporadic medullary thyroid carcinoma

Jingzhu Zhao1, Xiangqian Zheng1, Ming Gao2,(), Jiadong Chi1, Xinwei Yun1, Dapeng Li1, Xianhui Ruan1   

  1. 1. Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China
    2. Department of Breast and Thyroid Diseases, Tianjin Union Medical Center, Tianjin 300121, China
  • Received:2021-03-09 Published:2021-12-01
  • Corresponding author: Ming Gao
引用本文:

赵敬柱, 郑向前, 高明, 池嘉栋, 运新伟, 李大鹏, 阮先辉. 散发性甲状腺髓样癌原发灶的切除范围及预后分析[J/OL]. 中华普通外科学文献(电子版), 2021, 15(06): 429-431.

Jingzhu Zhao, Xiangqian Zheng, Ming Gao, Jiadong Chi, Xinwei Yun, Dapeng Li, Xianhui Ruan. Surgical selection and prognostic analysis of sporadic medullary thyroid carcinoma[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(06): 429-431.

目的

分析散发性甲状腺髓样癌原发灶切除范围及对预后的影响。

方法

收集2015年1月至2017年6月期间首诊于天津医科大学肿瘤医院65例散发性甲状腺髓样癌患者的临床资料,分为全甲状腺切除组(A组)和单侧腺叶及峡叶切除组(B组),比较两组患者临床病理特征、生化治愈、复发、无进展生存期。

结果

其中A组25例,B组40例。A组中Ⅰ+Ⅱ期患者8例(32.0%)低于B组23例(57.5%)(χ2=4.010,P=0.045),其余临床病例资料差异无统计学意义。中位随访时间35个月,生化治愈率67.9%(38/56),复发率18.5%(12/65)。A、B两组患者间生化治愈率(63.6% vs 70.6%)、复发率(28.0% vs 12.5%)及无进展生存期[(46.29±3.21)个月vs(61.94±3.58)个月],差异无统计学意义。

结论

对于散发性甲状腺髓样癌患者,并不一定均采取全甲状腺切除,可选择性行单侧腺叶切除。

Objective

To analyze the surgical resection range and prognosis of sporadic medullary thyroid carcinoma (MTC).

Methods

Clinical data of 65 sporadic MTC patients firstly treated in Tianjin Medical University Cancer Institute and Hospital from January 2015 to June 2017 were reviewed retrospectively. The patients were divided into total thyroidectomy group (group A) and unilateral lobectomy group (group B), the differences in clinicopathological characteristics, the biochemical cure, recurrence and progression-free survival were compared between the two groups.

Results

There were 25 cases in group A and 40 cases in group B. The ratio of stage Ⅰ+Ⅱ patients in group A (8/25, 32.0%) was significantly lower than that in group B (23/40, 57.5%) ( χ2=4.010, P=0.045), and there were no significant differences in the other clinicopathological characteristics between the groups. The median follow-up time was 35 months. The biochemical cure rate was 67.9% (38/56) and the recurrence rate was 18.5% (12/65). There were no significant differences in biochemical cure rate (63.6% vs 70.6%), recurrence rate (28.0% vs 12.5%) and progression-free survival [(46.29±3.21) months vs (61.94±3.58) months] between the groups.

Conclusion

For sporadic MTC patients, total thyroidectomy is not always necessary, and selective unilateral lobectomy is feasible.

表1 两组甲状腺髓样癌患者临床病理资料的比较
[1]
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6): 567-610.
[2]
Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems[J]. Cancer, 2000, 88(5): 1139-1148.
[3]
Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma[J]. Ann Surg, 1999, 230(5): 697-707.
[4]
Evans DB, Fleming JB, Lee JE, et al. The surgical treatment of medullary thyroid carcinoma[J]. Semin Surg Oncol, 1999, 16(1): 50-63.
[5]
Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2. 2018[J]. J Natl Compr Canc Netw, 2018, 16(12): 1429-1440.
[6]
董文武,张浩. 2018年版日本《甲状腺肿瘤诊疗指南》外科治疗部分更新解读[J]. 中国实用外科杂志, 2019, 39(12): 1260-1264.
[7]
王宇,田文,嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J].中国实用外科杂志, 2020, 40(9): 1012-1020.
[8]
程文元,徐本义,李树玲. 基础水平降钙素与甲状腺髓样癌颈淋巴结转移相关临床研究(附48例临床分析)[J]. 中国肿瘤临床与康复, 2002, 9(6): 79.
[9]
于洋,高明,冯影, 等. 甲状腺髓样癌外科处理与基因筛查原则探讨[J]. 中国肿瘤临床, 2007, 34(21): 1226-1228.
[10]
Miyauchi A, Matsuzuka F, Hirai K, et al. Unilateral surgery supported by germline RET oncogene mutation analysis in patients with sporadic medullary thyroid carcinoma[J]. World J Surg, 2000, 24(11): 1367-1372.
[11]
Miyauchi A, Matsuzuka F, Hirai K, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations[J]. World J Surg, 2002, 26(8): 1023-1028.
[12]
Ito Y, Miyauchi A, Yabuta T, et al. Alternative surgical strategies and favorable outcomes in patients with medullary thyroid carcinoma in Japan: experience of a single institution[J]. World J Surg, 2009, 33(1): 58-66.
[13]
Ito Y, Miyauchi A, Kihara M, et al. Static prognostic factors and appropriate surgical designs for patients with medullary thyroid carcinoma: the second report from a single-institution study in Japan[J]. World J Surg, 2018, 42(12): 3954-3966.
[14]
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases[J]. Cancer, 2006, 107(9): 2134-2142.
[1] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[2] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[3] 谢田伟, 庞于樊, 吴丽. 超声引导下不同消融术对甲状腺良性结节体积缩减率、复发率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 80-83.
[4] 王伟伟, 费建平, 王璋瑜. 不同手术空间建立方法的经口腔前庭入路腔镜甲状腺术对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 84-87.
[5] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[6] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[7] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[8] 高建新, 王啸飞, 于淼, 路夷平. 局部进展期直肠癌新辅助治疗后行ISR术远切缘距离的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 539-543.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[11] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[12] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[13] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[14] 杭丽, 张耀辉, 孙文恺. 参菝抗瘤液对结直肠腺瘤性息肉术后肠道功能、炎症指标及复发情况的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 413-416.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要